Transglutaminase 2: The Maestro of the Oncogenic Mediators in Renal Cell Carcinoma

• Main Authors: Ayca Ece Nezir, Burge Ulukan, Dilek Telci
• Format: Article
• Language: English
• Published: MDPI AG 2019-02-01
• Series: Medical Sciences
• Subjects: Transglutaminase 2 (TG2); Renal Cell Carcinoma (RCC); metastasis; invasion; epithelial mesenchymal transition
• Online Access: https://www.mdpi.com/2076-3271/7/2/24

Transglutaminase 2 (TG2) is a multifunctional crosslinking enzyme that displays transamidation, protein disulfide isomerase, protein kinase, as well as GTPase and ATPase activities. TG2 can also act as an adhesion molecule involved in the syndecan and integrin receptor signaling. In recent years, TG2 was implicated in cancer progression, survival, invasion, migration, and stemness of many cancer types, including renal cell carcinoma (RCC). Von Hippel-Lindau mutations leading to the subsequent activation of Hypoxia Inducible Factor (HIF)-1-mediated signaling pathways, survival signaling via the PI3K/Akt pathway resulting in Epithelial Mesenchymal Transition (EMT) metastasis and angiogenesis are the main factors in RCC progression. A number of studies have shown that TG2 was important in HIF-1- and PI3K-mediated signaling, VHL and p53 stabilization, glycolytic metabolism and migratory phenotype in RCC. This review focuses on the role of TG2 in the regulation of molecular pathways nurturing not only the development and propagation of RCC, but also drug-resistance and metastatic potential.